20-236 - A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate
Status: openRandomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)
Treatment for Oncology - Acute Myeloid Leukemia
Contact Us
If you have questions about this trial or are interested in participating, please contact Wendy Blount, director of clinical trials, at (251) 445-9834 or wlblount@health.southalabama.edu.
Description
The trial will evaluate how well venetoclax in combination with azacitidine (AZA) works as compared to best supportive care (BSC) as maintenance therapy in patients with Acute Myeloid Leukemia (AML) in first remission after completion of the first chemotherapy treatment regimen.
Providers Associated With This Trial
Principle Investigator
![Omar Alkharabsheh]()
View ProfileOmar Alkharabsheh, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology
Sub Investigators
![Thomas Butler]()
View ProfileThomas W. Butler, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Oncology
